Shandong Weigao Blood Purification Products Co., Ltd. (SHA:603014)

China · Delayed Price · Currency is CNY

35.21

-0.44 (-1.23%)

May 14, 2026, 4:00 PM EDT

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Medical Products	3.77B	3.60B	3.53B	3.43B	2.91B
Medical Products Growth	4.57%	2.03%	3.09%	17.71%	-
Total	3.77B	3.60B	3.53B	3.43B	2.91B
Total Growth	4.57%	2.03%	3.09%	17.71%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Mainland China	3.44B	3.40B	3.40B	3.36B	-
Mainland China Growth	1.13%	-0.03%	1.22%	-	-
Other Countries and Regions	329.26M	202.96M	129.94M	64.97M	48.73M
Other Countries and Regions Growth	62.23%	56.20%	99.99%	33.34%	-
China	-	-	-	-	2.73B
Total	3.77B	3.60B	3.53B	3.43B	2.78B
Total Growth	4.57%	2.03%	3.09%	23.33%	-

Source: S&P Global Market Intelligence.